In 540 adults with migraine, atogepant 60 mg daily led to fewer discontinuations for adverse events than topiramate over 24 weeks (12% vs 30%; RR 0·4). Secondary: ≥50% fewer migraine days in 64% vs 39%. Serious adverse events: six vs three.
RCTn = 545
Reuter et al. Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial